R243
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 45
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.550
- INTERFERON_GAMMA_RESPONSE+0.490
- ALLOGRAFT_REJECTION+0.470
- INFLAMMATORY_RESPONSE+0.400
- IL6_JAK_STAT3_SIGNALING+0.380
- TNFA_SIGNALING_VIA_NFKB+0.320
- KRAS_SIGNALING_UP+0.300
- COMPLEMENT+0.290
- APOPTOSIS+0.220
- COAGULATION+0.170
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.380
- WNT_BETA_CATENIN_SIGNALING-0.370
- MYC_TARGETS_V1-0.340
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.270
- UV_RESPONSE_DN-0.270
- ANDROGEN_RESPONSE-0.230
- TGF_BETA_SIGNALING-0.200
- MYC_TARGETS_V2-0.180
- UNFOLDED_PROTEIN_RESPONSE-0.170
- ADIPOGENESIS-0.160
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG943 | — | — | 0.872 |
| 2 | SRR1369219 | GTEX | — | 0.832 |
| 3 | f5760366-59eb-417d-a935-3f78e999dd42 | — | — | 0.831 |
| 4 | 39927c92-75d7-424c-9bcd-63def0075a1d | — | — | 0.830 |
| 5 | TCGA-PE-A5DE-01A-11R-A27Q-07 | — | D | 0.826 |
| 6 | ERR2208965 | — | — | 0.825 |
| 7 | SRR8518215 | — | D | 0.813 |
| 8 | MNG303 | — | — | 0.813 |
| 9 | MDT-AP-2234 | Med | Medulloblastoma | 0.811 |
| 10 | 5566453e-df41-4aab-8dd0-825efbece954 | — | — | 0.811 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.550 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.490 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.470 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.400 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.380 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.320 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.300 | Inavolisib | — uncovered |
| COMPLEMENT | 0.290 | Inavolisib | — uncovered |
| APOPTOSIS | 0.220 | Idelalisib | — uncovered |
| COAGULATION | 0.170 | Binimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.140 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.130 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.130 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.120 | Temsirolimus | — uncovered |
| APICAL_JUNCTION | 0.110 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.100 | Cobimetinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.080 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.070 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.040 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.020 | Remibrutinib | — uncovered |